Transcriptome Analysis Identified Elevated Expression of Bone Gamma-carboxyglutamic acid-containing Protein (BGLAP) in Human Cervical Cancer Tissues

Anjali Devi S. Bettadapura¹, Vijay K. Munivenkatappa² and SubbaRao V. Madhunapantula¹,³*

¹Department of Biochemistry, JSS Medical College, JSS Academy of Higher Education & Research, Mysuru - 570015, Karnataka, India.
²Department of Oncosurgery, Bharath Hospital and Institute of Oncology, Mysuru - 570 017, Karnataka, India.
³Leader, Special Interest Group in Cancer Biology and Cancer Stem Cells (SIG-CBSC), JSS Academy of Higher Education & Research, Mysuru - 570015, Karnataka, India.
*Corresponding author E-mail: mvsstsubbarao@jssuni.edu.in

http://dx.doi.org/10.13005/bpj/1472

(Received: 11 May 2018; accepted: 26 June 2018)

Carcinoma of cervix is one of the major health concerns among women. Although effective preventive methods are available to protect individuals from getting cervical cancer, the incidence and mortality rates due to this disease are increasing at alarming rates. In addition, currently, no potent treatment strategies exist to treat advanced cervical cancers. Therefore, identification of key biomarkers that indicate the severity and drug resistance of cervical cancers is of high importance. Comparative analysis of transcriptome of tumor- and normal tissue is one way of determining the deregulated genes, which serve as biomarkers. Hence, in this study the transcriptome of malignant cervical cancer tissues was compared with adjacent non-tumor tissue and genes that are at least 2-fold high were selected. Among various selected genes, Bone gamma carboxyglutamic acid containing protein (BGLAP, commonly known as Osteocalcin) was found consistently high in all the tumor tissue compared to adjacent non-tumor tissue. Hence, BGLAP could be a potential biomarker for identifying malignant cervical cancer tumors.

Keyword: Transcriptome, BGLAP, Cancer tissues.
death\(^3\). Despite several screening and vaccination programs, it is predicted that the mortality from cervical cancer will increase to ~45% by 2030\(^4\). According to national cancer registry, in India, approximately 113,138 new cervical cancer cases were detected in the year 2015 making it the third most common cancer\(^4\). Further analysis showed that about a quarter of cervical cancers diagnosed each year are from India\(^4\). Recent projections predicted an increase of up to 123,291 cases by the year 2020\(^4\). Therefore, the burden of cervical cancer continues to increase, especially in developing and under developed countries as it affects women in the productive age group of 20 to 59 years\(^5,6\). Early detection is one of the ways to reduce the mortality rates, and transcriptome analysis is an approach widely used to identify deregulated genes in cancer cells. Comparison of the transcriptomes of non-tumor and tumor tissues provide key information about the genes that are deregulated in tumors, hence, is a useful method to identify biomarkers of tumor progression and disease severity.

Transcriptome is the entire collection of genes that are transcribed in a particular cell, and is an indicator of gene expression\(^7\). In general, transcriptome is analyzed by, first, isolating the total RNA followed by separating the mRNA and measuring the level of expression based on the number of RNA transcripts (7.8). Sequencing of mRNA transcripts provide information even about the mutations present in genes\(^7,8\). Therefore, transcriptome analysis is an important tool not only to measure gene expression but also to identify genetic changes in a cell\(^7,8\). Hence, in this study the transcriptome analysis was carried out to determine the key genes that are deregulated in cervical cancer tissues compared to paired non-tumor tissue. One deregulated gene identified in this analysis is bone gamma-carboxyglutamic acid-containing protein (BGLAP)\(^9\).

BGLAP, also known as Osteocalcin, is a 11kDa protein hormone synthesized and secreted by osteoblasts\(^10\). Functionally, it regulates the mineralization of bone matrix and control coagulation of blood\(^11,12\). However, recent studies have implicated BGLAP in tumor progression and malignant transformation of cells\(^13,14\). For instance, elevated BGLAP was reported in carcinomas of prostate and breast, and has been shown to promote metastasis of these tumor cells to bone\(^13,14\). Similarly, a recent study evaluating the role of BGLAP in pancreatic cancer demonstrated a vital function to this protein in the survival and invasion of cells\(^15\). However, to date no study has reported the expression of BGLAP in cervical cancers. To the best of our knowledge, this is the first report mentioning the elevated expression of BGLAP in carcinomas of cervix. Future studies should evaluate the mechanisms by which BGLAP is promoting the growth of cervical cancer cells and whether targeted inhibition of BGLAP helps in retarding survival and spread of cells.

**MATERIALS AND METHODS**

**Collection of tissues**

Ethical committee clearance was taken before the commencement of the study (JSS/MC/IEC/4898/2012-2013 dated 22-12-2012). Paired cancerous- and adjacent non-cancerous tissues were collected from patients visiting the Department of Oncosurgery, Bharath Hospital and Institute of Oncology (a collaborative hospital located in Mysore) and JSS Hospital after obtaining informed consent. The samples were collected by punch biopsy. The study participants were not exposed to any form of cancer therapy. The collected tissues were immediately transferred to DNAse and RNAse free tubes containing RNA later solution (~500µL). The collected tissues were stored at -20°C freezer.

**Extraction of total RNA**

RNA extraction was carried out using Allprep RNA extraction kit from Qiagen India Pvt Ltd, New Delhi, India (Scheme #1). The kit extracts all RNA molecules that are longer than 200 nucleotides\(^16\). Procedurally, first, the tissues (30.0mg) were lysed and homogenized in a high-density guanidino isothiocyanate containing buffer to inactivate DNAses, RNAses and proteases. Next, the lysate was passed through DNA spin column, which facilitates the binding of total RNA to inactivate DNAses, RNAses and proteases. The column was washed thrice with wash buffer, and the bound DNA eluted. After this, the sample free of DNA was made to flow through the RNeasy spin column, which allows the binding of genomic DNA. The contaminants and impurities were washed and the bound RNA eluted using 30µL water.
Determination of the quality of isolated RNA

Quality of isolated RNA was assessed using tape-station. Principally, the tape-station works similar to agarose gel electrophoresis. Samples were prepared by adding 5.0µL buffer to 1.0µL RNA. Since RNAs possess tertiary structures, the samples were denatured by heating at 72°C for 2 minutes. The denatured samples were placed on ice (for 2 minutes) and quality scores determined by assessing RNA Integration Number (RIN). RIN is a software algorithm developed by Agilent technologies to analyze the quality of RNA. It considers the whole electrophoretogram into account before ascertaining an integer value. RIN ranges from 1 to 10, with 10 being the most intact and 1 being the most degraded RNA. Samples with RIN equal to or greater than 7 were used for library preparation in this study.

Quantification of isolated RNA using Qubit method

The amount of RNA present in the sample was determined using RNA HS assay kit fluorimetrically. Qubit RNA HS kit accurately determines the RNA concentration over a range of 250 pg/ml to 100ng/ml. Experimentally, first, the Qubit RNA HS reagent was diluted 1: 200 in Qubit RNA buffer solution. Next, the concentration curve was prepared by mixing 10.0µL standards with 190.0µL working solution. The samples (1.0 to 20.0µL) were prepared by adjusting the final volume to 200µL using Qubit working solution. All the tubes were incubated at room temperature for two minutes and the values read using Qubit fluorimeter operating with excitation filters: Blue 430–495nm; and Red 600–645nm; emission filters: Green 510–580nm, and Red 665–720nm.

Preparation of libraries

Step#1: Purification of mRNA and generation of fragments: mRNA from the total RNA was purified using magnetic beads that contain Oligo dT. Bound RNA was eluted by the addition of polyA RNA. Fragmentation of RNA was carried out during the elution of RNA from beads. Next, the primers for cDNA synthesis were added to the eluted fragmented RNA and the synthesized cDNA subjected for (a) end repair protocol to remove 3′ overhangs, and (b) filling the gaps in 5′ overhangs using polymerase. Next, the 3′ ends were adenylated by adding a single Adenylate nucleotide, which prevents the relegation. Next, the adapters were ligated and analyzed by flow cell hybridization. The adapters utilized are

TruSeq Universal Adapter:
5′AATGATACGGCGACCACCGAGATCTACACTCTTT
CCCTACACGACGTCTTCCGATCT3′

TruSeq Illumina Index Adapter:
5′GATCGGAAGAGCACACGTCTGATGC AATTTCACACCTGAC5′

DNA fragment enrichment

PCR was used to amplify DNA fragments. The program conditions used were detailed below: Initial denaturation: 98°C for 30 seconds
PCR cycles (15 cycles):
Denaturation: 98°C for 10 seconds; Annealing: 60°C for 30 seconds,
Elongation: 72°C for 30 seconds
Final extension: 72°C for 5 minutes
Storage: Hold at 10°C

After PCR amplification, the prepared library was quantified using Qubit DNA assay reagent kit (concentration range of 10.0pg/µL to 100.0ng/µL), and the size of DNA fragments determined using Tape station-2200, which has been designed to analyze DNA of size 35-1000bp

Normalization of library
DNA templates were prepared ready for cluster generation as detailed in

Cluster generation
The cluster generation was carried out by amplifying the library on a cBOT using solid phase PCR, (on a flow cell coated), with oligonucleotide probes. The dsDNA was denatured to single strands to enable the binding of primers for sequencing. The amplified libraries were sequenced using sequencing by synthesis method on HiSeq 4000 using 100bp paired end chemistry.

Analysis of sequenced data
The data acquired from fast-Q files (obtained from HiSeq 4000), was trimmed using the trimmomatic software version 0.036. Procedurally, the trimming protocol includes: (a) Removal of adaptors and other illumina specific sequences using Illumina Clip; (b) Trimming of reads with below the average quality by scanning from the 5′ end; (c) Maximization of the quality of each read by balancing error rate and read length; (d) Removal of bases at the start, and end
of the read respectively if the quality is below the threshold; (e) Elimination of bases from the start and end of the read; (f) Dropping of the reads of below minimum length; (g) Removal of reads below average quality; (h) Convert quality scores to Phred33 and Phred64.

**Contamination Removal**

Removal of Non mRNA and mitochondrial genome sequences The unwanted sequences that include – mitochondrial genome sequences, ribosomal RNAs, transfer RNAs, adapter sequences and others were removed using Bowtie 2 Version 2.2.4

**Read Alignment**

The paired-end reads were aligned to the reference human genome Feb. 2009 release, which was downloaded from UCSC database (GRCh37/hg19). The chromosome fasta file was downloaded from the website and alignment was performed using Hierarchical Indexing for Spliced Alignment of Transcripts program.

**Read Summarization**

Read summarization of the samples was estimated using Feature Counts (version 1.5.2). These counts mapped reads for genes, exons, promoter, gene bodies, genomic bins and chromosomal locations and can be used for both RNA and DNA sequences.

**Differential Expression**

The Differential expression analysis was performed using DESeq2. This program uses negative binomial distribution for analyzing differential gene expression (Scheme #1).

**RESULTS**

RNA isolated from tissues is not degraded and is suitable for cDNA library preparation

Total RNA from cervical cancer tissues as well as adjacent non-tumorous samples was isolated as detailed in materials and methods section and the quality and quantity determined using nanodrop spectrophotometer and Tape Station (Figure 1 and Table 1). Analysis of the data showed the presence of high quality RNA as evidenced by 260/280 ratio more than 2.0 for majority of samples, except non-cancerous tissue #5 (NC5, 260/280 = 1.70) and cancer tissue (CT5, 260/280 = 1.50).

---

Scheme 1. Flow chart depicting different steps in the transcriptome analysis
260/280 = 1.66). In addition, the RNA integration number (RIN), an indicator of RNA quality, is more than 7.0 for all the samples except cancer tissue #5 (CT5, RIN = 6.5) and non-cancerous tissue #1 (NC1, RIN = 6.8). Although RIN above 8.0 is considered of high quality, for tumor tissues values in the range of 6.0 to 8.0 are also considered suitable for library preparation (Table 1).

**BGLAP is upregulated in cervical cancer tissues compared to adjacent non-cancerous tissue**

Since the RNA isolated from cervical cancer tissues as well as adjacent non-cancerous
tissues is suitable for preparing the cDNA library, all the samples were processed for further processing as detailed in the Scheme #1. Analysis of the sequencing data followed by bioinformatics calculations identified BGLAP as one of the key genes upregulated constantly in all the samples (Figure 2A and 2B).

**DISCUSSION**

BGLAP the widely known Osteocalcin is a key oncogenic protein expressed by many metastatic tumors. Very recently Hayashi, Y et al., have demonstrated that osteocalcin regulates prostate cancer cells growth in a carboxylation dependent manner. For example, whereas the gammacarboxylated osteocalcin (GlaOC) promoted the proliferation of prostate cancer cells, the uncarboxylated osteocalcin retarded the cell growth by controlling the phosphorylation of receptor tyrosine kinases. Therefore, it is important to, first, measure the expression of Osteocalcin in tumor cells compared to adjacent non-cancerous tissues. In this study we have shown elevated expression of BGLAP in all the cervical cancer tissues compared to adjacent non-cancerous tissues indicating this could be a potent oncogene in cervical cancers. However, it is not known whether BGLAP expression at mRNA level also correlate with protein expression in tissues as well as in serum, if so, the expressed BGLAP is functionally active. More over it is also currently unknown whether any polymorphic forms of BGLAP are present in cervical cancer tissues. A study by Liu, Y et al., showed a significant association between the rs1800247 HH and Hh genotypes and increased susceptibility to hepatocellular carcinoma.

A separate study has demonstrated that BGLAP regulate tumor cell proliferation, survival and metastasis of pancreatic cells. Targeting knockdown BGLAP using siRNA or expressing TNF-a, a negative modulator of BGLAP in pancreatic cancers, reduced the proliferation and migration of pancreatic cancer cells. Hence, BGLAP is considered as a marker for tumor cell proliferation and migration.

Although many prior studies have reported newer pathways in cervical cancers based on transcriptome analysis, to date, no study has identified BGLAP as a key marker for metastatic cervical cancers. For example, a study by Campos-Parra, A.D. et al., 2016 analyzing the transcriptomes of 89 locally advanced cervical cancer tissues has shown over expression of 7530 genes related to 93 signaling pathways such as JAK-STAT, NOTCH and mTOR autophagy cascades. Many other studies have also carried out transcriptomic analysis of cervical cancer tissues and identified unique pathways. Even though we have identified BGLAP in this study, it’s expression in multiple sample needs to be tested and validation of its involvement needs to be experimentally confirmed using proof-of-principle studies. Therefore, future studies should measure the expression of BGLAP.

---

**Table 1. Qualitative and quantitative analysis of isolated RNA**

<table>
<thead>
<tr>
<th>Sample</th>
<th>A260/280 Ratio</th>
<th>A260/230 Ratio</th>
<th>QUBIT (ng/µl)</th>
<th>RIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-cancerous tissue #1</td>
<td>2.02</td>
<td>1.17</td>
<td>40.2</td>
<td>6.8</td>
</tr>
<tr>
<td>Non-cancerous tissue #2</td>
<td>2.07</td>
<td>2.14</td>
<td>414.0</td>
<td>8.0</td>
</tr>
<tr>
<td>Non-cancerous tissue #3</td>
<td>2.07</td>
<td>2.09</td>
<td>496.0</td>
<td>8.8</td>
</tr>
<tr>
<td>Non-cancerous tissue #4</td>
<td>2.13</td>
<td>0.53</td>
<td>72.0</td>
<td>7.9</td>
</tr>
<tr>
<td>Non-cancerous tissue #5</td>
<td>1.70</td>
<td>0.46</td>
<td>110 (1.4)</td>
<td>7.0</td>
</tr>
<tr>
<td>Cancer tissue #1</td>
<td>2.07</td>
<td>0.84</td>
<td>80.0</td>
<td>8.4</td>
</tr>
<tr>
<td>Cancer tissue #2</td>
<td>2.08</td>
<td>2.03</td>
<td>230.0</td>
<td>7.6</td>
</tr>
<tr>
<td>Cancer tissue #3</td>
<td>2.08</td>
<td>1.47</td>
<td>998.0</td>
<td>8.2</td>
</tr>
<tr>
<td>Cancer tissue #4</td>
<td>2.09</td>
<td>1.53</td>
<td>10.9</td>
<td>8.6</td>
</tr>
<tr>
<td>Cancer tissue #5</td>
<td>1.66</td>
<td>0.32</td>
<td>398</td>
<td>6.5</td>
</tr>
</tbody>
</table>
in the serum and tissues of cervical cancer patients and test whether knocking down has any impact in cervical cancer cell growth.

CONCLUSIONS

In summary, we have carried out the analysis of transcriptome of cervical cancer tissues and compared with adjacent non-cancerous tissues to identify key deregulated genes. Analysis of the data showed a consistent upregulation of BGLAP gene exclusively in cancer tissues but not in non-cancerous tissues, indicating it could be a potent therapeutic target in this cancer. However, additional studies are warranted to check its role in cervical cancer cells development, growth and metastasis.

REFERENCES


